Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant radiochemotherapy. The rate of pCR under ICIs combined with neoadjuvant radiochemotherapy was reported around 50%, which means more than half of those patients could not obtain pCR in reality. In order to explore a more effective mode of neoadjuvant therapy for ESCC, we designed this study to evaluate the effect of PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy in local advanced ESCC.

Who May Be Eligible (Plain English)

Who May Qualify: - diagnosed with esophageal squamous cell cancer; - staged with cT1N+M0/cT2-3N0-3M0; - experienced no cancer-related treatment; - ECOG 0-1; - Expected survival more than 6 months; - aimed at neoadjuvant therapy for surger; - have adquate organ function. Who Should NOT Join This Trial: - diagnosed with other types of cancer during last five years; - have a tendency to bleed; - accepted any type of cancer-related therapy. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * diagnosed with esophageal squamous cell cancer; * staged with cT1N+M0/cT2-3N0-3M0; * experienced no cancer-related treatment; * ECOG 0-1; * Expected survival more than 6 months; * aimed at neoadjuvant therapy for surger; * have adquate organ function. Exclusion Criteria: * diagnosed with other types of cancer during last five years; * have a tendency to bleed; * accepted any type of cancer-related therapy.

Treatments Being Tested

COMBINATION_PRODUCT

cadonilizumab combined with neoadjuvant radiochemotherapy

Subjects randomized to experimental arm will be treated with PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.

COMBINATION_PRODUCT

neoadjuvant radiochemotherapy

Subjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.

Locations (1)

the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China